Immunotherapy and chemo join forces against tough lymphoma

NCT ID NCT03011814

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This study tests two drugs—durvalumab (an immunotherapy) and lenalidomide (a chemotherapy drug)—alone or together in people with T-cell lymphoma that has returned or not responded to prior treatment. The goal is to find the best dose and see how well the combination works. About 78 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug) and lenalidomide (a chemotherapy drug)
What this could lead to: If successful, this could offer a new treatment option for people with T-cell lymphoma that has stopped responding to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULOTROPIC MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

folliculotropic mycosis fungoides mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULOTROPIC MYCOSIS FUNGOIDES RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA RECURRENT MATURE T- AND NK-CELL NON-HODGKIN LYMPHOMA RECURRENT MYCOSIS FUNGOIDES REFRACTORY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA REFRACTORY MYCOSIS FUNGOIDES REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED SEZARY SYNDROME

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
M D Anderson Cancer Center
WITHDRAWN

Houston, Texas, 77030, United States
Memorial Sloan-Kettering Cancer Center
WITHDRAWN

New York, New York, 10065, United States
Thomas Jefferson University Hospital
WITHDRAWN

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.